(c) 2024 PillSync.com

lithium carbonate 450 MG Extended Release Oral Tablet

INDICATIONS AND USAGE Lithium Carbonate Extended-Release Tablets are indicated in the treatment of manic episodes of manic-depressive illness. Maintenance therapy prevents or diminishes the intensity of subsequent episodes in those manic-depressive patients with a history of mania. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, aggressiveness and possibly hostility. When given to a patient experiencing a manic episode, Lithium Carbonate Extended-Release Tablets may produce a normalization of symptomatology within 1 to 3 weeks.

West-Ward Pharmaceuticals Corp.


3 months ago ROUND WHITE 54 346 lithium carbonate 450 MG Extended Release Oral Tablet

ROUND WHITE 54 346

HOW SUPPLIED

LITHIUM CARBONATE Extended-Release Tablets, USP 450 mg tablets are speckled, off-white to yellow, round biconvex tablets with “54 346” debossed on one side and scored on the other side. (NDC 0054-0020-25) Bottle of 100 Tablets Storage Conditions Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Distributed by: Hikma Pharmaceuticals USA Inc. Berkeley Heights, NJ 07922 C50000331/01 Revised October 2022


More pills like ROUND 54 346

Related Pills












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site